NewAmsterdam Pharma Company N.V. $NAMS Shares Purchased by First Turn Management LLC

First Turn Management LLC grew its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 24.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 893,473 shares of the company’s stock after purchasing an additional 176,502 shares during the quarter. NewAmsterdam Pharma accounts for 3.6% of First Turn Management LLC’s investment portfolio, making the stock its 11th biggest position. First Turn Management LLC owned 0.79% of NewAmsterdam Pharma worth $31,343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its stake in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares in the last quarter. Navalign LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $46,000. Empowered Funds LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $85,000. Finally, NBC Securities Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $86,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $30.40 on Friday. The business has a 50-day moving average of $33.44 and a 200-day moving average of $33.69. The company has a market capitalization of $3.55 billion, a PE ratio of -16.98 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.63 and a 1-year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. On average, equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $869,158.57. This trade represents a 72.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.74% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC boosted their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Guggenheim boosted their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Truist Financial assumed coverage on NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average target price of $48.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.